Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach

… Committee of the Korean Gastric Cancer … - Journal of gastric …, 2019 - synapse.koreamed.org
Background Gastric cancer is the most common cancer and the fourth most common cause
of cancer death in South Korea [1]. Despite the large number of gastric cancer patients …

Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer …

J Lee, DH Lim, S Kim, SH Park, JO Park… - Journal of clinical …, 2012 - ascopubs.org
Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the
first study to our knowledge to investigate the role of postoperative chemoradiotherapy …

[HTML][HTML] Clinical application of circulating tumor cells in gastric cancer

MW Lee, GH Kim, HK Jeon, SJ Park - Gut and liver, 2019 - ncbi.nlm.nih.gov
Early detection and accurate monitoring of cancer is important for improving clinical
outcomes. Endoscopic biopsy and/or surgical resection specimens are the gold standard for …

An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal …

S Kim, DH Lim, J Lee, WK Kang, JS MacDonald… - International Journal of …, 2005 - Elsevier
Purpose: The role of adjuvant chemoradiotherapy (CRT) in D2-resected gastric-cancer
patients has not been defined yet. We investigated the effect of postoperative …

[HTML][HTML] Simvastatin plus capecitabine–cisplatin versus placebo plus capecitabine–cisplatin in patients with previously untreated advanced gastric cancer: a double …

ST Kim, JH Kang, J Lee, SH Park, JO Park… - European journal of …, 2014 - Elsevier
Purpose We aimed to the addition of synthetic 3-hydroxy-3-methyglutaryl coenzyme A (HMG-
CoA) reductase inhibitor, simvastatin to capecitabine–cisplatin (XP) in patients with …

Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node …

TH Kim, SR Park, KW Ryu, YW Kim, JM Bae… - International Journal of …, 2012 - Elsevier
PURPOSE: To compare chemotherapy alone with chemoradiation therapy in stage III-IV
(M0) gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. METHODS …

[HTML][HTML] Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: a meta-analysis

HS Kim, JH Kim, HJ Jang, B Han, DY Zang - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Fibroblast growth factor receptor-2 (FGFR2) protein expression by immunohistochemistry
has been reported in up to 60% of patients with gastric cancer (GC). However, the …

Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery

C Yu, R Yu, W Zhu, Y Song, T Li - Journal of cancer research and clinical …, 2012 - Springer
Background The purpose of the current study is to evaluate the efficacy and complications of
concurrent chemoradiotherapy (CCRT) for the treatment of gastric cancer patients after …

Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy

JS Chang, JS Lim, SH Noh, WJ Hyung, JY An… - Radiotherapy and …, 2012 - Elsevier
BACKGROUND AND PURPOSE: To analyze patterns of regional recurrence after curative
gastrectomy and D2 lymph node dissection in patients with stage III (N3) gastric cancer …

Pathological features as predictors of recurrence after radical resection of gastric cancer

R Buzzoni, E Bajetta, M Di Bartolomeo… - Journal of British …, 2006 - academic.oup.com
Background The aim of this study was to investigate the pattern and timing of recurrence and
to determine associated risk factors after radical resection of gastric cancer including D2 …